Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.
The FDA has granted Fast Track designation to amezalpat (TPST-1120) for the treatment of patients with hepatocellular carcinoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results